During the recent session, Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s traded shares were 1.05 million, with the beta value of the company hitting 0.89. At the last check today, the stock’s price was $5.64, reflecting an intraday gain of 5.71% or $0.3. The 52-week high for the IOVA share is $18.33, that puts it down -225.0 from that peak though still a striking 10.46% gain since the share price plummeted to a 52-week low of $5.05. The company’s market capitalization is $1.72B, and the average intraday trading volume over the past 10 days was 7.53 million shares, and the average trade volume was 7.70 million shares over the past three months.
Iovance Biotherapeutics Inc (IOVA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. IOVA has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Iovance Biotherapeutics Inc (IOVA) registered a 5.71% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 5.71% in intraday trading to $5.64, hitting a weekly high. The stock’s 5-day price performance is -0.79%, and it has moved by -4.48% in 30 days. Based on these gigs, the overall price performance for the year is -38.37%. The short interest in Iovance Biotherapeutics Inc (NASDAQ:IOVA) is 63.91 million shares and it means that shorts have 6.96 day(s) to cover.
The consensus price target of analysts on Wall Street is $12.25, which implies an increase of 53.96% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.5 and $17 respectively. As a result, IOVA is trading at a discount of -201.42% off the target high and -32.98% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -8.25%. While earnings are projected to return 31.48% in 2025, the next five years will return 45.45% per annum.
IOVA Dividends
Iovance Biotherapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Iovance Biotherapeutics Inc insiders own 1.10% of total outstanding shares while institutional holders control 89.79%, with the float percentage being 90.78%. VANGUARD GROUP INC is the largest shareholder of the company, while 398.0 institutions own stock in it. As of 2024-06-30, the company held over 25.95 million shares (or 9.7478% of all shares), a total value of $208.12 million in shares.
The next largest institutional holding, with 25.93 million shares, is of PERCEPTIVE ADVISORS LLC’s that is approximately 9.7412% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $207.98 million.
Also, the Mutual Funds coming in first place with the largest holdings of Iovance Biotherapeutics Inc (IOVA) shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 8.72 shares. This amounts to just over 2.86 percent of the company’s overall shares, with a $49.65 million market value. The same data shows that the other fund manager holds slightly less at 7.13, or about 2.34% of the stock, which is worth about $40.6 million.
